MART-1(97-116)

MART-1(97-116) is a synthetic peptide fragment derived from the melanoma antigen recognized by T cells 1 (MART-1), also known as Melan-A. As a well-characterized epitope, this peptide represents amino acids 97 to 116 of the MART-1 protein and is widely utilized in immunological and cancer research. Its sequence is recognized by cytotoxic T lymphocytes (CTLs) in the context of major histocompatibility complex (MHC) molecules, making it a valuable tool for studies focused on antigen-specific immune responses. The defined structure and immunogenic properties of MART-1(97-116) position it as a key reagent for investigating mechanisms underlying tumor immunology, T cell activation, and antigen presentation.

Antigen presentation research: In the context of antigen processing and presentation studies, MART-1(97-116) serves as a model peptide for exploring MHC class I-restricted presentation pathways. Researchers employ this fragment to load antigen-presenting cells (APCs) in vitro, enabling precise investigation into how peptide-MHC complexes are formed, trafficked, and recognized by T cells. Such studies are fundamental to understanding cellular immune surveillance and the molecular events that drive recognition of tumor-associated antigens.

T cell activation assays: The peptide is extensively used in functional assays designed to evaluate the activation, proliferation, and cytotoxicity of MART-1-specific T cells. By pulsing target cells or APCs with this epitope, investigators can monitor T cell responses through cytokine release, proliferation assays, or cytotoxicity measurements. These applications are crucial for dissecting the specificity and potency of T cell responses against melanoma antigens, as well as for validating immune monitoring protocols in preclinical research.

Vaccine development research: MART-1(97-116) is also employed in the development and evaluation of peptide-based vaccine candidates targeting melanoma. Its well-defined immunogenicity allows for the assessment of peptide formulations, adjuvant combinations, and delivery systems aimed at eliciting robust antigen-specific T cell responses. Experimental vaccine studies often utilize this peptide to measure the induction of MART-1-specific immunity in vitro or in animal models, providing insights into the optimization of cancer immunotherapy strategies.

Immunological monitoring: In translational and preclinical studies, the peptide is utilized for immune monitoring applications, such as the detection and quantification of MART-1-specific T cells in peripheral blood samples. Techniques including ELISPOT, flow cytometry with tetramer staining, and intracellular cytokine staining rely on MART-1(97-116) to identify and characterize antigen-specific T cell populations. This enables researchers to track immune responses in various experimental settings and to correlate T cell dynamics with disease progression or therapeutic interventions.

Epitope mapping and specificity studies: The defined sequence of MART-1(97-116) makes it an indispensable reagent for mapping T cell epitopes and studying the specificity of T cell receptor (TCR) recognition. Researchers use this peptide to delineate the minimal epitope required for T cell activation, to analyze cross-reactivity with related peptides, and to investigate the structural determinants of TCR-peptide-MHC interactions. Such studies provide valuable information for designing targeted immunotherapies and for understanding the molecular basis of antigen recognition in tumor immunity.

1. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes